Reinsurance Group of America RGA shares have rallied 41.6% year to date (YTD) compared with the industry's growth of 31.5%. The Finance sector and the Zacks S&P 500 index have returned 20.9% and 24.5% YTD, respectively. With a market capitalization of $15.09 billion, the average volume of shares traded in the last three months was 0.3 million. Currently priced at $229.17, the stock is a little below its 52-week high of $233.14.
Image Source: Zacks Investment Research
The rally was driven by its strong momentum in U.S. Traditional, Longevity/PRT, Asia Asset-Intensive and Asia Traditional, along with solid growth projections.
This Zacks Rank #2 (Buy) life insurer is trading above its 50-day and 200-day simple moving average (SMA) of $218.40 and $203.60, respectively, indicating solid upward momentum. SMA is a widely used technical analysis tool to predict future price trends by analyzing historical price data.
Reinsurance Group has a decent earnings surprise history. Its earnings beat estimates in each of the last four quarters, with an average surprise of 17.74%.
The Zacks Consensus Estimate for Reinsurance Group’s 2024 earnings per share indicates a year-over-year increase of 10.3%. The consensus estimate for revenues is pegged at $22.36 billion, implying a year-over-year improvement of 17.4%. The consensus estimate for 2025 earnings per share indicates a year-over-year increase of 3.7% from the corresponding 2024 estimates.
The expected long-term earnings growth rate is 10.4%, outperforming the industry average of 4.6%. RGA has an impressive Growth Score of B. This style score helps analyze the growth prospects of a company.
Its return on invested capital (ROIC) has increased every year. This reflects RGA’s efficiency in utilizing funds to generate income. ROIC in the trailing 12 months was 6.4%, higher than the industry average of 0.6%.
Two of the six analysts covering the stock have raised estimates for 2024, and three analysts have raised the same for 2025 over the past 30 days. The consensus estimate for 2024 and 2025 has moved 0.6% and 1.1% north, respectively, in the past 30 days.
Reinsurance Group is a leader in the U.S. and Latin American traditional markets. It has successfully expanded its product line with market-leading services, capabilities, expertise and innovation. Individual mortality has matured and provides a base for stable earnings and capital generation.
Significant value embedded in the in-force business is anticipated to generate predictable long-term earnings. Product-line expansion contributes to risk diversification.
In Canada, Reinsurance Group is a market leader with solid growth and profitability. It has a sizable block of in-force business, which acts as a significant source of future earnings. Reinsurance Group expects longevity insurance, which is projected to witness steady demand, to experience long-term growth in the Canadian market. While longevity insurance provides a source of diversified income, it also acts as a hedge to a large mortality position.
Demand for protection products among the emerging global middle class and increasing demand for retirement, senior protection and savings products among aging populations create opportunities for growth in new business.
RGA is well-capitalized and has access to multiple forms of capital. RGA expects to remain active in deploying capital in attractive growth opportunities while balancing returning excess capital to shareholders over time.
RGA continues to ramp up technological inclusion with its product. This insurer is a global biometric liability reinsurance leader. Biometrics experience, which includes mortality, morbidity and longevity, over the last five quarters was favorable.
Its free cash flow conversion has remained more than 85% over the last many quarters, reflecting its solid earnings.
RGA has a VGM Score of A. VGM Score helps identify stocks with the most attractive value, best growth and the most promising momentum. Back-tested results show that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best opportunities in the value investing space.
This global reinsurer has also been managing capital effectively via share buybacks, dividend payments and prudent investments. RGA expects to remain active in deploying capital into attractive growth opportunities in organic flow and in-force block transactions and returning excess capital to shareholders through dividends and share repurchases. The company exited the second quarter of 2024 with excess capital of around $0.7 billion, reflecting a solid capital position.
Investors interested in the life insurance industry may look at some other top-ranked players like Abacus Life, Inc. ABL, Manulife Financial Corp MFC and Primerica, Inc. PRI, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Abacus Life’s 2024 and 2025 earnings implies year-over-year growth of 19.2% and 22.4%, respectively. The Zacks Consensus Estimate for 2024 and 2025 revenues implies year-over-year growth of 33.1% and 57%, respectively. Year to date, shares of ABL have lost 9.8%.
The Zacks Consensus Estimate for Manulife Financial’s 2024 and 2025 earnings implies year-over-year growth of 6.6% and 9.2%, respectively. It beat earnings estimates in each of the past four quarters, with an average surprise of 5.36%. Year to date, shares of MFC have risen 47.9%.
The Zacks Consensus Estimate for Primerica’s 2024 and 2025 earnings implies year-over-year growth of 18.9% and 7.9%, respectively. It beat earnings estimates in two of the past four quarters and missed in two, with an average surprise of 4.89%. Year to date, shares of PRI have climbed 44.3%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Manulife Financial Corp (MFC) : Free Stock Analysis Report
Reinsurance Group of America, Incorporated (RGA) : Free Stock Analysis Report
Primerica, Inc. (PRI) : Free Stock Analysis Report
Abacus Life, Inc. (ABL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.